Indications
Therapeutic Asset Ratings
18,139 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Down Syndrome
National Cancer Institute (NCI)
P3
B
(63)
Cyclophosphamide
Fallopian Tube Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
P3
B
(63)
Cyclophosphamide
Gastric Cancer
Vall d'Hebron Institute of Oncology
P3
B
(63)
Cyclophosphamide
High Grade B-Cell Lymphoma
National Cancer Institute (NCI)
P3
B
(63)
Cyclophosphamide
Lung Neoplasm
Pfizer
P3
B
(63)
Cyclophosphamide
Marginal Zone Lymphoma
Paolo Caimi, MD
P3
B
(63)
Cyclophosphamide
Metastatic Melanoma
East Metropolitan Health Service, Australia
P3
B
(63)
Cyclophosphamide
Renal Pelvis Urothelial Carcinoma
Fred Hutchinson Cancer Center
P3
B
(63)
Cyclophosphamide
Ureter Transitional Cell Carcinoma
Fred Hutchinson Cancer Center
P3
B
(63)
Cyclophosphamide
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in Oncology
P3
B
(63)
Cyclophosphamide
Chronic Progressive Multiple Sclerosis
Bruce Cree
P3
B
(63)
Cyclophosphamide
Papillary Renal Cell Carcinoma
First Affiliated Hospital, Sun Yat-Sen University
P3
B
(63)
Cyclophosphamide
T-Cell Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
P3
B
(63)
Cytarabine
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
First Affiliated Hospital of Zhejiang University
P3
B
(63)
Cytarabine
Down Syndrome
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
P3
B
(63)
Cytarabine
T-Lymphoblastic Lymphoma
Children's Oncology Group
P3
B
(63)
Dabrafenib
Cutaneous Melanoma
Immuneering Corporation
P3
B
(63)
Dacarbazine
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)
P3
B
(63)
Dacarbazine
Nodular Sclerosis Classical Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
B
(63)
Dacarbazine
Hodgkin'S Lymphoma, Lymphocytic Depletion
National Cancer Institute (NCI)
P3
B
(63)
Dacarbazine
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)
P3
B
(63)
Dacarbazine
Soft Tissue Sarcoma
Institut Bergonié
P3
B
(63)
Darolutamide
Metastatic Prostate Carcinoma
West China Hospital
P3
B
(63)
Dasatinib
Childhood Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(63)
Daunomycin
Down Syndrome
National Hospital Organization Nagoya Medical Center
P3
B
(63)
Showing 2701 to 2725 of 18,139 assets
Previous
Page 109 of 726
Next